</s><s> human papillomavirus quadrivalent ( types 6, 11, 16, and 18 ) vaccine, recombinant, was approved by the us food and drug administration for use in the united states in 2014. 
 the vaccine was approved on the basis of safety and efficacy studies demonstrating no evidence of impaired fertility or harm to the fetus. from 2006 through 2014 
, approximately 67 million doses were distributed to a total of 25,063,3,064 women in the us, and a registry for females inadvertently vaccinated during pregnancy was established by the manufacturer as part of its postlicensure commitment to the us department of health and human services. </s>